Document is current
Any future updates will be listed below
-
Authors
Yerrabelli, Rahul S. https://orcid.org/0000-0002-7670-9601
He, Ping
Fung, Edward K.
Kramer, Kim
Zanzonico, Pat B.
Humm, John L.
Guo, Hongfen
Pandit-Taskar, Neeta
Larson, Steven M.
Cheung, Nai-Kong V.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
- License Information
-
More Information
Article History
Received: 13 August 2020
Accepted: 20 September 2020
First Online: 13 October 2020
Compliance with ethical standards
:
: NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity in Y-Mabs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor and owner of issued patents licensed by MSK to Ymabs Therapeutics, Biotec Pharmacon, and Abpro-labs. Naxitamab and omburtamab were licensed by MSK to Y-mabs Therapeutics. Both MSK and NKC have financial interest in Y-mabs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics.
: Prior to enrolling patients, the human subjects research described in this article was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center and listed on (NCT00089245). All patients taking part in the study or their legal guardian provided informed consent to participate in the clinical trial. This study was performed in line with the principles of the Declaration of Helsinki.
: Data and computational parameters used in MATLAB are supplied as supplement to this manuscript. The model and ready-to-run code to run it have been made available in reference [].
